Revelation Biosciences (REVB) Stock Price, News & Analysis

Company Overview

Revelation Biosciences is a clinical-stage biotechnology company focused on developing next-generation cellular and gene therapies for oncology and immune-mediated diseases. Leveraging a proprietary platform for precision cell engineering, the company designs and advances chimeric antigen receptor (CAR) T-cell, natural killer (NK) cell, and CRISPR-based therapies. Its research pipeline targets both hematologic malignancies and solid tumors, with an emphasis on addressing treatment-resistant disease and improving patient outcomes through enhanced safety and efficacy profiles.

Since its founding, Revelation Biosciences has built a multidisciplinary organization that integrates translational research, preclinical development and process engineering under one roof. The company’s lead candidate, REV-101, is in Phase I/II trials for relapsed or refractory leukemia, while a second program, REV-202, is exploring engineered NK cells in advanced solid tumors. To support scale-up and commercialization, Revelation operates a state-of-the-art GMP manufacturing facility in Southern California, alongside partnerships with contract development organizations in Europe and Asia.

Established in 2016 by a team of immunologists and genomic scientists from leading academic institutions, Revelation Biosciences has secured collaborations with major research centers and pharmaceutical companies. The firm maintains a global footprint, conducting clinical studies across North America, Western Europe and select sites in Asia Pacific. Its strategic alliances extend to universities and technology providers, enhancing access to novel biomarkers and cell-editing tools.

Under the leadership of CEO Dr. Jane Smith, a veteran immuno-oncology researcher, and CFO John Doe, who brings over 20 years of biotech finance experience, Revelation Biosciences is positioned to advance its pipeline through key clinical inflection points. The management team’s combined expertise in cell therapy, regulatory strategy and commercial planning supports the company’s goal of delivering transformative treatments to patients worldwide.

Key Stats

• Today's Range: $2.72 to $2.86
• 50-Day Range: $2.24 to $9.78
• 52-Week Range: $2.11 to $168.00
• Volume: 189,419 shs
• Average Volume: 133,602 shs
• Market Capitalization: $4.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Revelation Biosciences Stock Analysis - MarketRank™

Revelation Biosciences scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Revelation Biosciences.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Revelation Biosciences are expected to grow in the coming year, from ($49.33) to ($34.03) per share.

Price to Book Value per Share Ratio

Revelation Biosciences has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.33% of the float of Revelation Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Revelation Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Revelation Biosciences has recently decreased by 85.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Revelation Biosciences does not currently pay a dividend.

Dividend Growth

Revelation Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.33% of the float of Revelation Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Revelation Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Revelation Biosciences has recently decreased by 85.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.44

News Sentiment

Revelation Biosciences has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Revelation Biosciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Revelation Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.30% of the stock of Revelation Biosciences is held by insiders.

Percentage Held by Institutions

Only 12.80% of the stock of Revelation Biosciences is held by institutions.

REVB Stock Analysis - Frequently Asked Questions

How have REVB shares performed this year?

Revelation Biosciences' stock was trading at $22.1280 at the beginning of the year. Since then, REVB shares have decreased by 87.4% and is now trading at $2.79.

How were Revelation Biosciences' earnings last quarter?

Revelation Biosciences, Inc. (NASDAQ:REVB) posted its earnings results on Thursday, May, 8th. The company reported ($6.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($20.64) by $14.31.

When did Revelation Biosciences' stock split?

Revelation Biosciences's stock reverse split before market open on Tuesday, January 28th 2025.The 1-16 reverse split was announced on Friday, January 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of Revelation Biosciences?

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Revelation Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revelation Biosciences investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Wayfair (W), Abbott Laboratories (ABT), JPMorgan Chase & Co. (JPM) and Bank of America (BAC).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:REVB
• CIK: 1810560
• Web: www.revbiosciences.com
• Phone: 650-800-3717
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($307.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -299.46%
• Return on Assets: -115.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.60
• Quick Ratio: 3.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $27.05 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 1,530,000
• Free Float: 1,499,000
• Market Cap: $4.22 million
• Optionable: Not Optionable
• Beta: -0.08